<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>VASOPRESSINÂ - argipressinÂ injection, solutionÂ </strong><br>General Injectables &amp; Vaccines, Inc<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>  VASOPRESSIN INJECTION, USP<br>Synthetic<br>Rx Only
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Vasopressin Injection, USP is a sterile, aqueous solution of synthetic vasopressin (8-L-arginine vasopressin) of the posterior pituitary gland for intramuscular or subcutaneous use. It is substantially free from the oxytocic principle and is standardized to contain 20 pressor units/mL. Each mL contains:Â  Vasopressin 20 units, Sodium Chloride 9 mg, Chlorobutanol 0.5% (as a preservative), Water for Injection q.s. pH (range 2.5 - 4.5) adjusted with Acetic Acid. The structural formula is:</p>
<p></p>
<p><img alt="Formula1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=977ab16e-c2c1-4aa2-98cb-af065b37c944&amp;name=Formula1.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The antidiuretic action of vasopressin is ascribed to increasing reabsorption of water by the renal tubules.</p>
<p>Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract and of all parts of the vascular bed, especially the capillaries, small arterioles and venules with less effect on the smooth musculature of the large veins. The direct effect on the contractile elements is neither antagonized by adrenergic blocking agents nor prevented by vascular denervation.</p>
<p>Following subcutaneous or intramuscular administration of vasopressin injection, the duration of antidiuretic activity is variable but effects are usually maintained for 2-8 hours.</p>
<p>The majority of a dose of vasopressin is metabolized and rapidly destroyed in the liver and kidneys. Vasopressin has a plasma half-life of about 10 to 20 minutes. Approximately 5% of a subcutaneous dose of vasopressin is excreted in urine unchanged after four hours.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>  INDICATIONS AND USAGE
</h1>
<p class="First">Vasopressin is indicated for prevention and treatment of postoperative abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, in abdominal roentgenography to dispel interfering gas shadows, and in <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>  CONTRAINDICATION
</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>  WARNINGS
</h1>
<p class="First">This drug should not be used in patients with vascular disease, especially disease of the coronary arteries, except with extreme caution. In such patients, even small doses may precipitate <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal pain</span>, and with larger doses, the possibility of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> should be considered.</p>
<p>Vasopressin may produce <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>. The early signs of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">listlessness</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> should be recognized to prevent terminal <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>  PRECAUTIONS
</h1>
<p class="First"><span class="Bold">General:Â  </span>Vasopressin should be used cautiously in the presence of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or any state in which a rapid addition to extracellular water may produce hazard for an already overburdened system.</p>
<p><span class="product-label-link" type="condition" conceptid="312358" conceptname="Chronic glomerulonephritis">Chronic nephritis</span> with nitrogen retention contraindicates the use of vasopressin until reasonable nitrogen blood levels have been attained.</p>
<p><span class="Bold">Information for Patients:Â  </span>Side effects such as <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">blanching of skin</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> may be reduced by taking 1 or 2 glasses of water at the time of vasopressin administration. These side effects are usually not serious and probably will disappear within a few minutes.</p>
<p><span class="Bold">Laboratory Tests:Â  </span>Electrocardiograms (ECG) and fluid and electrolyte status determinations are recommended at periodic intervals during therapy.</p>
<p><span class="Bold">Drug Interactions:Â  </span>1) The following drugs may potentiate the antidiuretic effect of vasopressin when used concurrently:Â  carbamazepine; chlorpropamide; clofibrate; urea; fludrocortisone; tricyclic antidepressants. 2) The following drugs may decrease the antidiuretic effect of vasopressin when used concurrently:Â  demeclocyline; norepinephrine; lithium; heparin, alcohol. 3) Ganglionic blocking agents may produce a marked increase in sensitivity to the pressor effects of vasopressin.</p>
<p><span class="Bold">Pregnancy:Â  </span><span class="Underline">Teratogenic Effects</span> - Pregnancy Category C. Animal reproduction studies have not been conducted with vasopressin. It is also not known whether vasopressin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Vasopressin should be given to a pregnant woman only if clearly needed.</p>
<p><span class="Bold">Labor and Delivery:Â  </span>Doses of vasopressin sufficient for an antidiuretic effect are not likely to produce tonic uterine contractions that could be deleterious to the fetus or threaten the continuation of the pregnancy.</p>
<p><span class="Bold">Nursing Mothers:Â  </span>Caution should be exercised when vasopressin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>  ADVERSE REACTIONS
</h1>
<p class="First">Local or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> may occur in hypersensitive individuals. The following side effects have been reported following the administration of vasopressin.</p>
<p><span class="Bold">Body as a Whole:Â  </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and/or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) has been observed shortly after injection of vasopressin.</p>
<p><span class="Bold">Cardiovascular:Â  </span><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, circumoral <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, angina, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">peripheral vasoconstriction</span> and <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>.</p>
<p><span class="Bold">Gastrointestinal:Â  </span><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, passage of gas.</p>
<p><span class="Bold">Nervous System:Â  </span><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, â€œpoundingâ€? in head.</p>
<p><span class="Bold">Respiratory:Â  </span>bronchial constriction.</p>
<p><span class="Bold">Skin and Appendages:Â  </span><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, cutaneous <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>  OVERDOSAGE
</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">Water intoxication</span> may be treated with water restriction and temporary withdrawal of vasopressin until <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> occurs. Severe <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> may require osmotic <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> with mannitol, hypertonic dextrose, or urea alone or with furosemide.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>  DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Vasopressin may be administered intramuscularly or subcutaneously.</p>
<p>Ten units of vasopressin (0.5 mL) will usually elicit full physiologic response in adult patients; 5 units will be adequate in many cases. Vasopressin should be given intramuscularly at three- or four-hour intervals as needed. The dosage should be proportionately reduced for children. (For an additional discussion of dosage, consult the sections below.)</p>
<p>When determining the dose of vasopressin for a given case, the following should be kept in mind.</p>
<p>It is particularly desirable to give a dose not much larger than is just sufficient to elicit the desired physiologic response. Excessive doses may cause undesirable side effects - <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">blanching</span> of the skin, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> - which, though not serious, may be alarming to the patient. Spontaneous recovery from such side effects occurs in a few minutes. It has been found that one or two glasses of water given at the time vasopressin is administered reduce such symptoms.</p>
<p><span class="Bold">Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Distention</span>:Â  </span>In the average postoperative adult patient, give 5 units (0.25 mL) initially, increase to 10 units (0.5 mL) at subsequent injections if necessary. It is recommended that vasopressin be given intramuscularly and that injections be repeated at three- or four-hour intervals as required. Dosage to be reduced proportionately for children.</p>
<p>Vasopressin used in this manner will frequently prevent or relieve postoperative distension. These recommendations apply also to <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> complicating <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> or other acute toxemias.</p>
<p><span class="Bold">Abdominal Roentgenography:Â  </span>For the average case, two injections of 10 units each (0.5 mL) are suggested. These should be given two hours and one-half hour, respectively, before films are exposed. Many roentgenologists advise giving an enema prior to the first dose of vasopressin.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span>:Â  </span>Vasopressin may be given by injection or administered intranasally on cotton pledgets, by nasal spray, or by dropper. The dose by injection is 5 to 10 units (0.25 to 0.5 mL) repeated two or three times daily as needed. When vasopressin is administered intranasally by spray or on pledgets, the dosage and interval between treatments must be determined for each patient.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Vasopressin Injection, USP 20 units/mL is supplied as follows:</p>
<p>For intramuscular or subcutaneous use:</p>
<p>NDC 0517-0510-25Â Â Â Â  10 units per 0.5 mL multiple dose vialÂ Â Â Â  Boxes of 25</p>
<p>NDC 0517-1020-25Â Â Â Â  20 units per 1 mL multiple dose vialÂ Â Â Â Â Â Â  Boxes of 25</p>
<p>NDC 0517-0410-10Â Â  Â  200 units per 10 mL multiple dose vialÂ Â Â  Boxes of 10</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) (See USP Controlled Room Temperature).</p>
<p></p>
<p>IN1020</p>
<p>Rev. 11/11</p>
<p>MG #8192</p>
<p><span class="Bold">AMERICAN REGENT, INC.</span></p>
<p><span class="Bold">SHIRLEY, NY 11967</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>SAMPLE PACKAGE LABEL</h1>
<p class="First"><img alt="Label1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=977ab16e-c2c1-4aa2-98cb-af065b37c944&amp;name=Label1.jpg"></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VASOPRESSINÂ 		
					</strong><br><span class="contentTableReg">argipressin injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52584-020(NDC:0517-1020)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ARGIPRESSIN</strong> (ARGIPRESSIN) </td>
<td class="formItem">ARGIPRESSIN</td>
<td class="formItem">20Â [USP'U] Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52584-020-25</td>
<td class="formItem">1  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">08/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>General Injectables &amp; Vaccines, Inc
							(108250663)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8ebcc433-5493-4dae-86e9-256410d1a236</div>
<div>Set id: 977ab16e-c2c1-4aa2-98cb-af065b37c944</div>
<div>Version: 6</div>
<div>Effective Time: 20130410</div>
</div>
</div>Â <div class="DistributorName">General Injectables &amp; Vaccines, Inc</div></p>
</body></html>
